We knew that biotech companies were lighting up the stock market this year. Today, the National Venture Capital Association has fresh numbers illustrating Wall Street’s love affair with life sciences entrepreneurs—and the corresponding cold shower awaiting their counterparts in the tech sector. The new report, comparing venture-backed IPOs with merger-and-acquisition deals, shows life sciences companies accounting for 13 of the 21 public stock listings in the second quarter.

We knew that biotech companies were lighting up the stock market this year. Today, the National Venture Capital Association has fresh numbers illustrating Wall Street’s love affair with life sciences entrepreneurs—and the corresponding cold shower awaiting their counterparts in the tech sector.

The new report, comparing venture-backed IPOs with merger-and-acquisition deals, shows life sciences companies accounting for 13 of the 21 public stock listings in the second quarter.

To read the full, original article click on this link: Wall St. Loves Biotech, Leading Venture-Backed IPOs in Q2 | Xconomy